Bir Yıl Sonunda Şehirde Yaşayan Türk Kadınındaki Human Papilloma Virus Persistans ve Klereansı

Abstract

Amaç: Marmara Üniversitesi Hastanesi kadın hastalıkları polikliniğinde human papilloma virüs (HPV) pozitif saptanan kadınlarda değişik HPV genotiplerinin persistansını değerlendirmek.

Hastalar ve Yöntem: İlk prevalans çalışmasında HPV DNA testi pozitif saptanan 79 kadından 40'ı bir yıl sonra tekrar değerlendirildi. HPV tipleri polymerase chain reaction (PCR) ve mikroarray hibridizasyon teknikleri ile tanımlandı.

Bulgular: İlk değerlendirmenin bir yıl sonrasında kadınların %52,5'nin HPV enfeksiyonunun ortadan kalktığı; %35 ‘inin yeni bir HPV enfeksiyonu edindiği saptandı. 40 kadının %17,5'inde HPV DNA persistansı saptandı. Dokuz kadın aynı filogenetik ağaçtan HPV genotipi edinmişti. Yüksek riskli (YR) HPV tipi enfeksiyonun %43,33'ü ve düşük riskli (DR) HPV tipi enfeksiyonun %80'i ortadan kalkmıştı.

Sonuç: Yüksek riskli HPV tipleri saptanan kadınlarda persistans oranı artmıştı. Çok sayıda ve karışık tipte HPV enfeksiyonları HPV genotipinin persistansında önemli etkiye sahiptir. (Marmara Üniversitesi Tıp Fakültesi Dergisi 2012;25:10-5)

Keywords

• Servikal sitoloji, HPV genotipi, HPV persistansı, HPV kliransı

The Persistence and Clearance Rate of Human Papilloma Virus Genotypes in Urban Turkish Women after One Year

Abstract

Objective: To evaluate the persistence of the different human papillomavirus
(HPV) genotypes in women detected positive for HPV at Marmara University
Hospital gynecologic outpatient clinics.
Patients and Methods: Forty out of 79 women who had been tested
positive for HPV DNA in our initial prevalance study were re-assessed after
one year. HPV types were identified by polymerase chain reaction (PCR)
and hybridization using a microarray.
Results: One year after the initial assessment, 52.5% of the women had their
initial HPV infection resolved and 35% of the women had acquired another
HPV infection. The HPV DNA persistence was detected in 17.5% of the
40 women. Nine women had acquisition of HPV genotype by the same
phylogenetic clade. 43.33% of high risk (HR) HPV type and 80% of the low
risk (LR) HPV type infection had resolved.
Conclusions: The persistence rate was increased in women with HR HPV
types. Multiple and mixed HPV infections have an important impact on the
persistence of HPV genotype. (Marmara Medical Journal 2012;25:10-5)
Key Words: Cervical cytology, HPV genotype, HPV persistence, HPV clearance

Keywords

• Cervical cytology
• HPV genotype
• HPV persistence
• HPV clearance

References

1. CDC. Epidemiology and Prevention of Vaccine-Preventable Diseases.
2. Atkinson W, Wolfe S, Hambrosky J, et al, eds. 11th ed. Washington,
3. DC: Public Health Foundation; 2009.
4. Baseman J, Koutsky L. The epidomiology of human papillomavirus
5. infections. J Clin Virol 2005;32(Suppl 1):S16–24. doi
6. 1016/j.jcv.2004.12.008
7. Clifford GM, Gallus S, Herrero R, et al. Worldwide distribution of
8. human papillomavirus types in cytologically normal women in the

9. International Agency for Research on Cancer HPV prevalence surveys:
10. a pooled analysis. Lancet 2005; 366: 991–8. doi 10.1016/S0140-
11. (05)67069-9
12. Eren F, Erenus M, Bas E, et al. Prevalence of HPV infection by cytologic
13. diagnosis and HPV DNA extraction and prevalence of the HPV
14. genotypes detected in urban Turkish women, Int J Gynecol Obstet
15. ;109: 235-8. doi 10.1016/j.ijgo.2010.01.007
16. Hildesheim A, Schiffman MH,Gravitt PE, et al. Persistence of typespecific
17. human papillomavirus infection among cytologically normal
18. women. J Infect Dis 1994;169:235–40.
19. Ho GY, Bierman R, Beardsley L, et al. Natural history of cervicovaginal
20. papillomavirus infection in young women. N Engl J Med
21. ;338:423–8. doi 10.1056/NEJM199802123380703
22. Elfgren K, Kalantari M, Moberger B, et al. A population based five-year
23. follow-up study of cervical human papillomavirus infection. Am J
24. Obstet Gynecol 2000;183:561–7. doi 10.1067/mob.[phone]
25. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is
26. a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;
27. : 12–19. doi 10.1002/(SICI)1096-9896(199909)189:1<12::AIDPATH431>3.0.CO;2-F
28. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human
29. papillomavirus in cervical cancer: a worldwide perspective.
30. International biological study on cervical cancer (IBSCC study group).
31. J Natl Cancer Inst 1995; 87:796–802.
32. Marmara Medical Journal 2012;25:10-5
33. Yoldemir et al. 14 The Increased Persistence Rate with High Risk HPV Types
34. Rozendaal L, Walboomers JM, van der Linden JC, et al. PCR-based
35. high-risk HPV test in cervical cancer screening gives objective risk
36. assessment of women with cytomorphologically normal cervical
37. smears. Int J Cancer 1996;68:766–9. doi 10.1002/(SICI)1097-
38. (19961211)68:6<766::AID-IJC13>3.0.CO;2-Z
39. Kjaer SK, van den Brule AJ, Paull G, et al. Type specific persistence of
40. high risk human papillomavirus (HPV) as indicator of high grade
41. cervical squamous intraepithelial lesions in young women:
42. population based prospective follow up study. BMJ 2002;325:572–6.
43. Wallin KL, Wiklund F, Angström T, et al. Type-specific persistence of
44. human papillomavirus DNA before the development of invasive
45. cervical cancer. N Engl J Med 1999;341:1633-8. doi
46. 1056/NEJM199911253412201
47. Remmink AJ, Walboomers JM, Helmerhorst TJ, et al. The presence of
48. persistent high-risk HPV genotypes in dysplastic cervical lesions is
49. associated with progressive disease: natural history up to 36 months.
50. Int J Cancer 1995;61:306–11.
51. Schlecht NF, Kulaga S, Robitaille J, et al. Persistent human
52. papillomavirus infection as a predictor of cervical intraepithelial
53. neoplasia. JAMA 2001;286:3106–14.
54. Einstein MH, Burk RD. Persistent human papillomavirus infection:
55. definitions and clinical implications. Papillomavirus Report
56. ;12:119 -23.
57. Hinchliffe SA, VanVclzen D, Korporaal H, et al. Transience of cervical
58. HPV infection in sexually active young women with normal
59. cervicovaginal cylology. Br J Cancer 1995:72:943-5.
60. Ho GY, Burk RD, Klein S, et al. Persistent genital human papillomavirus
61. infection as a risk factor for persistent cervical dysplasia. J Natl Cancer
62. lnst 1995:87:1365-71.
63. Kirnbauer R, Booy F, Cheng N, et al. Papillomavirus L1 major capsid
64. protein self-assembles into virus like particles that are highly
65. immunogenic. Proc Natl Acad Sci USA 1992;89:80-4.
66. Woodman CB, Collins S, Winter H, et al. Natural history of cervical
67. human papillomavirus infection in young women: a longitudinal
68. cohort study. Lancet 2001;357: 1831–6. doi 10.1016/S0140-
69. (00)04956-4
70. Molano M, Van den Brule A, Plummer M, et al. Determinants of
71. clearance of human papillomavirus infections in Colombian women
72. with normal cytology: a population-based, 5-year follow-up study.
73. Am J Epidemiol 2003;158:486–94.
74. Franco EL, Villa LL, Sobrinho JP, et al. Epidemiology of acquisition and
75. clearance of cervical human papillomavirus infection in women from
76. a high-risk area for cervical cancer. J Infect Dis 1999;180:1415–23.
77. doi 10.1086/315086
78. Richardson H, Kelsall G, Tellier P, et al. The natural history of typespecific
79. human papillomavirus infections in female university
80. students. Cancer Epidemiol Biomarkers Prev 2003;12:485–90.
81. Brisson J, Bairati I, Morin C, et al. Determinants of persistent detection
82. of human papillomavirus DNA in the uterine cervix. J Infect Dis 1996;
83. : 794–9.
84. Thomas KK, Hughes JP, Kuypers JM, et al. Concurrent and sequential
85. acquisition of different genital human papillomavirus types. J Infect
86. Dis 2000;182:1097–102. doi 10.1086/315805
87. Perrons C, Jelley R, Kleter B, et al. Detection of persistent high risk
88. human papillomavirus infections with hybrid capture II and
89. SPF10/LiPA. J Clin Virol 2005;32: 278–85. doi
90. 1016/j.jcv.2004.08.009
91. Liaw KL, Hildesheim A, Burk RD, et al. A prospective study of human
92. papillomavirus (HPV) type 16 DNA detection by polymerase chain
93. reaction and its association with acquisition and persistence of other
94. HPV types. J Infect Dis 2001;183:8–15. doi 10.1086/317638
95. Rousseau MC, Abrahamowicz M, Villa LL, et al. Predictors of cervical
96. coinfection with multiple human papillomavirus types. Cancer
97. Epidemiol Biomarkers Prev 2003;12:1029–37.
98. Zielinski GD, Snijders PJF, Rozendaal L, et al. HPV presence precedes
99. abnormal cytology in women developing cervical cancer and signals
100. false negative smears Br J Cancer 2001; 85: 398–404. doi
101. 1054/bjoc.2001.1926
102. Lorincz AT, Castle PE, Sherman ME, et al. Viral load of human
103. papillomavirus and risk of CIN3 or cervical cancer. Lancet
104. ;360:228–9. doi 10.1016/S0140-6736(02)09463-1
105. Herrero R, Hildesheim A, Bratti C, et al. Population based study of
106. human papillomavirus infection and cervical neoplasia in rural Costa
107. Rica. J Natl Cancer Inst 2000;92:464–74.
108. Hall S, Lorincz A, Shah F, et al. Human papillomavirus DNA detection
109. in cervical specimens by hybrid capture: correlation with cytologic and
110. histologic diagnoses of squamous intraepithelial lesions of the cervix.
111. Gynecol Oncol 1996;62: 353–9. doi 10.1006/gyno.1996.0248
112. Nindl I, Greinke C, Zahm DM, et al. Human papillomavirus distribution
113. in cervical tissues of different morphology as determined by hybrid
114. capture assay and PCR. Int J Gynecol Pathol 1997; 16: 197–204.
115. Swan DC, Tucker RA, Tortolero-Luna G, et al. Human papillomavirus
116. (HPV) DNA copy number is dependent on grade of cervical disease
117. and HPV type. J Clin Microbiol 1999:37; 1030–4.
118. Heard I, Tassie JM, Schmitz V, et al. Increased risk of cervical disease
119. among human immunodeficiency virus-infected women with severe
120. immunosuppression and high human papillomavirus load(1). Obstet
121. Gynecol 2000;96: 403–9.
122. Clavel C, Masure M, Levert M, et al. Human papillomavirus detection
123. by the hybrid capture II assay: a reliable test to select women with
124. normal cervical smears at risk for developing cervical lesions. Diagn
125. Mol Pathol 2000;9:145–150.
126. van Duin M, Snijders PJ, Schrijnemakers HF, et al. Human
127. papillomavirus 16 load in normal and abnormal cervical scrapes: an
128. indicator of CIN II/III and viral clearance. Int J Cancer 2002;98:590–5.
129. Crum CP, Beach KJ, Hedley ML, et al. Dynamics of human
130. papillomavirus infection between biopsy and excision of cervical
131. intraepithelial neoplasia: results from the ZYC101a protocol. J Infect
132. Dis 2004;189: 1348–54. doi 10.1086/382956
133. Koshiol J, Lindsay L, Pimenta J M, et al. Persistent human papillomavirus
134. infection and cervical neoplasia: A systematic review and meta-analysis.
135. Am J Epidemiol 2008;168:123–37. doi 10.1093/aje/kwn036
136. Kovacic MB, Castle PE., Herrero R, et al. Relationships of human
137. papillomavirus type, qualitative viral load, and age with cytologic
138. abnormality. Cancer Res 2006; 66: 10112-9. doi 10.1158/0008-
139. CAN-06-1812
140. Nielsen A, Kjaer SK, Munk C, Iftner T. Type-specific HPV infection and
141. multiple HPV types: prevalence and risk factor profile in nearly 12000
142. younger and older Danish women. Sex Transm Dis 2008;35:276–82.
143. doi 10.1097/OLQ.0b013e31815ac5c7